アフターアワーズ： 1.40 0.005 +0.36%

Theriva Biologics Inc (TOVX)

概要ニュース株価時系列ディスカッション予測

Theriva Biologics Inc (TOVX) 最新ニュース

Theriva Biologics Inc (TOVX)

Theriva Biologics Inc (TOVX) 最新ニュース

Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Up 6.8% – Should You Buy? - Defense World

Theriva Biologics Announces Presentation of Data from the - GlobeNewswire

Major Clinical Trial Update: Theriva's SYN-004 Shows Promise in Transplant PatientsKey Data Revealed - Stock Titan

Synthetic Biologics stock plunges to 52-week low at $1.02 - Investing.com Australia

Synthetic Biologics stock plunges to 52-week low at $1.02 By Investing.com - Investing.com South Africa

Theriva Biologics Completes Enrollment For VIRAGE Trial, Topline Data Expected In Q2 2025 - Nasdaq

Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Ad - GlobeNewswire

Cancer Drug Breakthrough: Independent Committee Confirms Positive Safety Data in Phase 2b Pancreatic Trial - Stock Titan

Theriva Biologics (NYSEAMERICAN:TOVX) Shares Down 1.4% – Should You Sell? - Defense World

Theriva Biologics to Present at the CAGLA NeauxCancer 2025 Conference in New Orleans - Nasdaq

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference - GlobeNewswire

Theriva Biologics Reports 2024 Financial Results and Progress - TipRanks

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results - The Manila Times

Can Theriva's PDAC Trial Success and FDA Fast Track Save Its Dwindling Cash Position? - StockTitan

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual - The Manila Times

Cancer Therapeutics Company Theriva Sets Key Investor Presentation DateWhat to Expect - StockTitan

Theriva Biologics Inc Inc. (TOVX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle

US Stocks To Open Higher On Shortened Trading Day: Santa Claus Rally Period Officially Begins, Says Analyst - Benzinga

Why Carbon Revolution Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket - Benzinga

Synthetic Biologics stock hits 52-week low at $1.21 - Investing.com India

Synthetic Biologics stock hits 52-week low at $1.21 By Investing.com - Investing.com UK

Theriva Biologics outlines Phase 3 study for cancer drug By Investing.com - Investing.com Canada

Theriva™ Biologics Announces U.S. FDA Guidance on Design of - GlobeNewswire

Theriva Biologics Gets FDA Guidance on VCN-01 Phase 3 Trial Design for Pancreatic Cancer Treatment - StockTitan

Synthetic Biologics stock hits 52-week low at $1.24 By Investing.com - Investing.com South Africa

Synthetic Biologics stock hits 52-week low at $1.24 - Investing.com

Maxim Group Has Lowered Expectations for Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price - Defense World

Theriva Biologics Highlights Key Achievements in Q3 2024 - TipRanks

Theriva Biologics: Q3 Earnings Snapshot - Houston Chronicle

Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results - GlobeNewswire

Theriva Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

What's Going On With Theriva Biologics Stock Friday? - MSN

Theriva Biologics Expands Stock Plans and Share Authority - TipRanks

Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant - GlobeNewswire

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma - Yahoo Finance

Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - The Globe and Mail

Synthetic Biologics stock plunges to 52-week low of $1.24 - Investing.com

Theriva Biologics dips 11%, prices 2.5M equity offering - MSN

Theriva Biologics Announces Pricing of $2.5 Million Public Offering - GlobeNewswire

Synthetic Biologics stock plunges to 52-week low of $2.66 - Investing.com

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer - Yahoo Finance

Theriva™ Biologics Awarded Manufacturing Funding from the - GlobeNewswire

Theriva Biologics (TOVX) Is Making Noise With a Promising Pipeline - Nasdaq

Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket - Benzinga

What's Going On With Theriva Biologics Stock? - Benzinga

Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga

TOVXに似た銘柄